Everest Medicines Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 1,290

Employees

  • Stock Symbol
  • 01952

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.19
  • (As of Tuesday Closing)

Everest Medicines General Information

Description

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 17/F, AIA Financial Center
  • 866 East Changzhi Road, Hongkou District
  • Shanghai, 200082
  • China
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
HKG
Corporate Office
  • 17/F, AIA Financial Center
  • 866 East Changzhi Road, Hongkou District
  • Shanghai, 200082
  • China

Everest Medicines Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Everest Medicines Stock Performance

As of 17-Nov-2026, Everest Medicines’s stock price is $3.19. Its current market cap is $1.13B with 354M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.19 $3.28 $2.89 - $6.47 $1.13B 354M 9.6M -$0.02

Everest Medicines Financials Summary

As of 30-Jun-2026, Everest Medicines has a trailing 12-month revenue of $344M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 841,754 1,559,934 1,809,384 547,548
Revenue 344,186 237,325 98,485 17,800
EBITDA (28,158) (67,283) (136,685) (120,468)
Net Income (7,706) (41,406) (145,130) (119,361)
Total Assets 1,242,975 976,886 679,285 814,374
Total Debt 292,849 132,388 75,238 72,035
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Everest Medicines Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Everest Medicines‘s full profile, request access.

Request a free trial

Everest Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commerc
Pharmaceuticals
Shanghai, China
1,290 As of 2026

Mississauga, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Everest Medicines Competitors (1)

One of Everest Medicines’s competitors is Sumitomo Pharma (Pharmaceuticals), a Corporation company based in Mississauga, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sumitomo Pharma (Pharmaceuticals) Corporation Mississauga, Canada
You’re viewing 1 of 1 competitors. Get the full list »

Everest Medicines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Everest Medicines Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Everest Medicines‘s full profile, request access.

Request a free trial

Everest Medicines Investments & Acquisitions (2)

Everest Medicines’s most recent deal was a Merger/Acquisition with Hasten Biopharmaceuticals (SG) for . The deal was made on 09-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hasten Biopharmaceuticals (SG) 09-Apr-2026 Merger/Acquisition Distributors/Wholesale
NovaBridge Biosciences 05-Aug-2025 PIPE Drug Discovery
To view Everest Medicines’s complete investments and acquisitions history, request access »

Everest Medicines ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.13 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Everest Medicines’s complete esg history, request access »

Everest Medicines FAQs

  • When was Everest Medicines founded?

    Everest Medicines was founded in 2017.

  • Where is Everest Medicines headquartered?

    Everest Medicines is headquartered in Shanghai, China.

  • What is the size of Everest Medicines?

    Everest Medicines has 1,290 total employees.

  • What industry is Everest Medicines in?

    Everest Medicines’s primary industry is Pharmaceuticals.

  • Is Everest Medicines a private or public company?

    Everest Medicines is a Public company.

  • What is Everest Medicines’s stock symbol?

    The ticker symbol for Everest Medicines is 01952.

  • What is the current stock price of Everest Medicines?

    As of 17-Nov-2026 the stock price of Everest Medicines is $3.19.

  • What is the current market cap of Everest Medicines?

    The current market capitalization of Everest Medicines is $1.13B.

  • What is Everest Medicines’s current revenue?

    The trailing twelve month revenue for Everest Medicines is $344M.

  • Who are Everest Medicines’s competitors?

    Sumitomo Pharma (Pharmaceuticals) is a competitor of Everest Medicines.

  • What is Everest Medicines’s annual earnings per share (EPS)?

    Everest Medicines’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process